Molecular pathology and prostate cancer therapeutics: From biology to bedside

Journal of Pathology

Volumn 232, Issue 2, 2014, Pages 178-184

  Rodrigues, Daniel Nava ^a   Butler, Lisa M ^b   Estelles, David Lorente ^a   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

castration resistant; molecular pathology; prostate cancer; targeted therapy

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; APR 246; AURORA A KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN P53; RADIUM CHLORIDE RA 223; SIPULEUCEL T; TEMSIROLIMUS; TESTOSTERONE; UNCLASSIFIED DRUG; VELIPARIB; ZOLEDRONIC ACID;

ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; BONE DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DIARRHEA; DNA REPAIR; DRUG APPROVAL; DRUG TOLERABILITY; FEEDBACK SYSTEM; GENE MUTATION; HOT FLUSH; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; IMMUNOGENICITY; IMMUNOSURVEILLANCE; LOW DRUG DOSE; MOLECULAR PATHOLOGY; NEUROENDOCRINE PROSTATE CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

CASTRATION-RESISTANT; MOLECULAR PATHOLOGY; PROSTATE CANCER; TARGETED THERAPY;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; DNA REPAIR; DRUG DISCOVERY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PHENOTYPE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84890259591     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4272     Document Type: Review

References (67)

1. Jemal A, Bray F, Center MM, et al., Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Bostwick DG, Cheng L., Urologic Surgical Pathology, 2nd edn. Mosby, Elsevier: Maryland Heights, MO.
3. Curtis C, Shah SP, Chin SF, et al., The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
4. Daraselia N, Wang Y, Budoff A, et al., Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am J Cancer Res 2012; 2: 93-103.
5. Wang R, Hu H, Pan Y, et al., RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012; 30: 4352-4359.
6. Huggins C SJR, Hodges CV,. The effect of castration on advanced carcinoma of the prostate gland. Arch Surgry 1941; 43: 209.
7. Gelmann EP,. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20: 3001-3015.
8. Edwards J, Bartlett JM,. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 2005; 95: 1320-1326.
9. Green SM, Mostaghel EA, Nelson PS,. Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol 2012; 360: 3-13.
10. Heemers HV, Tindall DJ,. Androgen receptor (AR) coregulators a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808.
11. Cunha GR, Donjacour AA, Cooke PS, et al., The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-362.
12. Yeh S, Tsai MY, Xu Q, et al., Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci USA 2002; 99: 13498-13503.
13. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
14. Lim AC, Attard G,. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer. Curr Drug Targets 2013; 14: 408-419.
15. Ryan CJ, Tindall DJ,. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 3651-3658.
16. Scher HI, Buchanan G, Gerald W, et al., Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 2004; 11: 459-476.
17. Tomlins SA, Laxman B, Varambally S, et al., Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-188.
18. Tomlins SA, Rhodes DR, Perner S, et al., Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
19. Haffner MC, Aryee MJ, Toubaji A, et al., Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42: 668-675.
20. Lin C, Yang L, Tanasa B, et al., Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139: 1069-1083.
21. Tran C, Ouk S, Clegg NJ, et al., Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
22. Scher HI, Fizazi K, Saad F, et al., Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
23. Eichholz A, Ferraldeschi R, Attard G, et al., Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. Mol Cell Endocrinol 2012; 360: 68-75.
24. Attard G, Reid AH, A'Hern R, et al., Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748.
25. de Bono JS, Logothetis CJ, Molina A, et al., Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
26. Ryan CJ, Smith MR, de Bono JS, et al., Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148.
27. Attard G, Swennenhuis JF, Olmos D, et al., Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69: 2912-2918.
28. Attard G, De Bono JS, Li W, et al., ERG rearrangements and association with clinical outcomes in patiensts receiving abiraterone acetate (AA): results from COU-AA-302 study in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2013; 31 (suppl); abstr 5004.
29. Bilke S, Schwentner R, Yang F, et al., Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res 2013; 23: 1797-1809.
30. Li C, Ao J, Fu J, et al., Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011; 30: 4350-4364.
31. Liu J, Ghanim M, Xue L, et al., Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 2009; 323: 1218-1222.
32. Barbieri CE, Baca SC, Lawrence MS, et al., Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-689.
33. Tomlins SA, Rhodes DR, Yu J, et al., The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008; 13: 519-528.
34. Ateeq B, Tomlins SA, Laxman B, et al., Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 2011; 3: 72ra17.
35. Berger MF, Lawrence MS, Demichelis F, et al., The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-220.
36. McPherson A, Wu C, Wyatt AW, et al., nFuse: discovery of complex genomic rearrangements in cancer using high-throughput sequencing. Genome Res 2012; 22: 2250-2261.
37. Baca SC, Prandi D, Lawrence MS, et al., Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666-677.
38. Brenner JC, Ateeq B, Li Y, et al., Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011; 19: 664-678.
39. Schiewer MJ, Goodwin JF, Han S, et al., Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2012; 2: 1134-1149.
40. Kote-Jarai Z, Leongamornlert D, Saunders E, et al., BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230-1234.
41. Castro E, Goh C, Olmos D, et al., Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748-1757.
42. Sandhu SK, Omlin A, Hylands L, et al., Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 2013; 24: 1416-1418.
43. Beltran H, Yelensky R, Frampton GM, et al., Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013; 63: 920-926.
44. Lehmann S, Bykov VJ, Ali D, et al., Targeting p53 in vivo a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30: 3633-3639.
45. Tovar C, Higgins B, Kolinsky K, et al., MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer 2011; 10: 49.
46. Sarker D, Reid AH, Yap TA, et al., Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805.
47. Pourmand G, Ziaee AA, Abedi AR, et al., Role of PTEN gene in progression of prostate cancer. Urol J 2007; 4: 95-100.
48. King JC, Xu J, Wongvipat J, et al., Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009; 41: 524-526.
49. Reid AH, Attard G, Ambroisine L, et al., Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010; 102: 678-684.
50. Amato RJ, Jac J, Mohammad T, et al., Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer 2008; 6: 97-102.
51. Bendell JC, Rodon J, Burris HA, et al., Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282-290.
52. Yap TA, Yan L, Patnaik A, et al., First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011; 29: 4688-4695.
53. Abrahamsson PA,. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135-148.
54. Mosquera JM, Beltran H, Park K, et al., Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013; 15: 1-10.
55. Leibovici D, Spiess PE, Agarwal PK, et al., Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007; 109: 198-204.
56. Mazzucchelli R, Lopez-Beltran A, Cheng L, et al., Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int 2008; 102: 1369-1374.
57. di Sant'Agnese PA,. Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate Suppl 1998; 8: 74-79.
58. Nikonova AS, Astsaturov I, Serebriiskii IG, et al., Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 2013; 70: 661-687.
59. Bischoff JR, Anderson L, Zhu Y, et al., A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17: 3052-3065.
60. Mita M, Gordon M, Rejeb N, et al. A phase I study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol 2013; (in press).
61. Saad F, Gleason DM, Murray R, et al., A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
62. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer a randomised, double-blind study. Lancet 2011; 377: 813-822.
63. 223Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62: 3120-3125.
64. Parker C, Nilsson S, Heinrich D, et al., α-Emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.
65. Kantoff PW, Higano CS, Shore ND, et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
66. Higano CS, Schellhammer PF, Small EJ, et al., Integrated data from two randomized, double-blind, placebo-controlled, phase III trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-3679.
67. Sandhu SK, Schelman WR, Wilding G, et al., The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer a phase I dose-escalation trial. Lancet Oncol 2013; 14: 882-892.